Basic Info
  • Grade: pharmaceutical grade

    Factory Location: Shandong

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Adaptation: For locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one previous chemotherapy regimen Pharmacology: Erlotinib is an inhibitor of epidermal growth factor receptor tyrosine kinase. Erlotinib can compete with ATP to bind the intracellular catalytic region of epidermal growth factor receptor tyrosine kinase, inhibit phosphorylation, block and inhibit the system's transmission of intranuclear information, and thus prevent tumor growth, control cell proliferation, neovascularization and tumor metastasis
Send your message to this supplier
  • From:
  • To:
    SHANDONG FENGJIN PHARMACEUTICAL CO.,LTD.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service